Thrombocytopathy vs Platelet hyper-reactivity in COVID-19: diverse pathologies, disease outcomes and therapeutic implications
Coagulopathy is an evident complication of COVID-19 with predominance of a prothrombotic state. Platelet activation plays a key role. The terms “hyper-reactivity” and “hyperactivity” used in recent literature may not be clear or sufficient to explain the pathological events involved in COVID-related...
Main Authors: | Ali Tafazoli, Shreya Anil Kumar, Maha Othman |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2022-01-01
|
Series: | Platelets |
Online Access: | http://dx.doi.org/10.1080/09537104.2021.1961718 |
Similar Items
-
Thrombocytopathies: Not Just Aggregation Defects—The Clinical Relevance of Procoagulant Platelets
by: Alessandro Aliotta, et al.
Published: (2021-02-01) -
Platelet reactivity in dyslipidemia: atherothrombotic signaling and therapeutic implications
by: Moua Yang, et al.
Published: (2021-03-01) -
High On-Treatment Platelet Reactivity in Danish Hyper-Acute Ischaemic Stroke Patients
by: Charlotte L. Rath, et al.
Published: (2018-08-01) -
Chemokines and their role in airway hyper-reactivity
by: Hogaboam Cory M, et al.
Published: (2000-07-01) -
Is Platelet Reactivity a Therapeutic Target to Limit Microvascular Obstruction?
by: Jaclyn Carberry, et al.
Published: (2022-02-01)